The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...
An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
The FDA has approved Zepbound, a weight-loss medication, as the first drug treatment for moderate to severe obstructive sleep ...
The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep expert Dr. Wendy Troxel discusses the impact of the new development.
Averaging up to 20% of weight loss, adults taking Zepbound had 25 fewer breathing interruptions each hour as they slept.
Among the many newcomers to the business of weight-loss drugs is Hims & Hers, an American e-pharmacy better known for hawking ...